- In January 2024, Sichuan Jinjiang Electronic Medical Device Technology Co. Ltd. secured approval from China's National Medical Products Administration (NMPA) for its pulsed field ablation (PFA) technology designed for treating atrial fibrillation. This marks a significant milestone, as it becomes the first PFA device to receive commercial approval in China. The introduction of this innovative technology is expected to enhance treatment options for patients with atrial fibrillation in the region
- In April 2023, Fujifilm Healthcare Corporation announced the transfer of its electronic medical record (EMR) and medical receipt systems business to PHC Holdings Corporation. This move comes as part of a stock purchase agreement, positioning PHC Holdings, the parent company of Medicom medical information systems, to further enhance its offerings in healthcare technology. The transition aims to streamline operations and leverage synergies between the two organizations to better serve the medical community
- In October 2021, the Salk Institute initiated a phase 1 clinical trial to evaluate the safety of CMS121, a novel medication for Alzheimer's disease. This study aims to assess how the drug interacts with participants, providing crucial insights into its safety profile. The findings from this trial are expected to pave the way for further research into the medication's efficacy and potential applications in treating Alzheimer's
